INFINITY PHARMACEUTICALS INC's ticker is INFI and the CUSIP is 45665G303. A total of 131 filers reported holding INFINITY PHARMACEUTICALS INC in Q3 2015. The put-call ratio across all filers is 0.76 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2021 | $285,000 | +52.4% | 88,100 | 0.0% | 0.00% | – |
| Q4 2020 | $187,000 | +81.6% | 88,100 | 0.0% | 0.00% | – |
| Q3 2020 | $103,000 | +28.8% | 88,100 | 0.0% | 0.00% | – |
| Q2 2020 | $80,000 | +8.1% | 88,100 | 0.0% | 0.00% | – |
| Q1 2020 | $74,000 | -12.9% | 88,100 | 0.0% | 0.00% | – |
| Q4 2019 | $85,000 | -6.6% | 88,100 | 0.0% | 0.00% | – |
| Q3 2019 | $91,000 | -42.8% | 88,100 | 0.0% | 0.00% | – |
| Q2 2019 | $159,000 | -4.2% | 88,100 | 0.0% | 0.00% | – |
| Q1 2019 | $166,000 | +59.6% | 88,100 | 0.0% | 0.00% | – |
| Q4 2018 | $104,000 | -56.5% | 88,100 | 0.0% | 0.00% | – |
| Q3 2018 | $239,000 | +42.3% | 88,100 | 0.0% | 0.00% | – |
| Q2 2018 | $168,000 | -9.2% | 88,100 | 0.0% | 0.00% | – |
| Q1 2018 | $185,000 | +3.4% | 88,100 | 0.0% | 0.00% | – |
| Q4 2017 | $179,000 | +53.0% | 88,100 | 0.0% | 0.00% | – |
| Q3 2017 | $117,000 | -15.2% | 88,100 | 0.0% | 0.00% | – |
| Q2 2017 | $138,000 | -51.6% | 88,100 | 0.0% | 0.00% | – |
| Q1 2017 | $285,000 | +129.8% | 88,100 | -4.1% | 0.00% | – |
| Q4 2016 | $124,000 | -13.3% | 91,900 | 0.0% | 0.00% | – |
| Q3 2016 | $143,000 | +9.2% | 91,900 | -6.5% | 0.00% | – |
| Q2 2016 | $131,000 | -75.5% | 98,300 | -3.1% | 0.00% | -100.0% |
| Q1 2016 | $534,000 | -36.8% | 101,400 | -5.8% | 0.00% | 0.0% |
| Q4 2015 | $845,000 | -7.0% | 107,600 | 0.0% | 0.00% | -50.0% |
| Q3 2015 | $909,000 | -22.8% | 107,600 | 0.0% | 0.00% | 0.0% |
| Q2 2015 | $1,178,000 | -30.9% | 107,600 | 0.0% | 0.00% | 0.0% |
| Q1 2015 | $1,704,000 | 0.0% | 107,600 | 0.0% | 0.00% | 0.0% |
| Q4 2014 | $1,704,000 | +18.0% | 107,600 | 0.0% | 0.00% | 0.0% |
| Q3 2014 | $1,444,000 | +5.3% | 107,600 | 0.0% | 0.00% | 0.0% |
| Q2 2014 | $1,371,000 | +20.8% | 107,600 | 0.0% | 0.00% | 0.0% |
| Q1 2014 | $1,135,000 | -17.6% | 107,600 | 0.0% | 0.00% | 0.0% |
| Q4 2013 | $1,378,000 | -28.0% | 107,600 | -1.9% | 0.00% | -50.0% |
| Q3 2013 | $1,914,000 | +28.5% | 109,700 | +19.8% | 0.00% | +33.3% |
| Q2 2013 | $1,489,000 | – | 91,600 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,354,963 | $38,132,000 | 1.80% |
| Orbimed Advisors | 4,520,800 | $73,201,000 | 1.55% |
| QVT Financial LP | 1,326,610 | $21,480,000 | 1.44% |
| BB BIOTECH AG | 1,089,828 | $17,646,000 | 1.27% |
| Meditor Group Ltd | 250,000 | $4,048,000 | 0.55% |
| Perimeter Capital Partners, LLC | 159,915 | $2,589,000 | 0.50% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 156,808 | $2,539,000 | 0.43% |
| Broadfin Capital, LLC | 117,172 | $1,897,000 | 0.37% |
| OXFORD ASSET MANAGEMENT LLP | 811,331 | $13,184,000 | 0.36% |
| Baker Brothers Advisors | 1,016,433 | $16,458,000 | 0.33% |